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1867Numerous reports have identiﬁed substantive sex differences
in the accuracy of diagnostic testing (1–7). Recent reports have
revealed improvements in the estimation of female-speciﬁc
risk in large cohorts of women undergoing stress echocardi-
ography and single-photon emission computed tomographic
(SPECT) imaging (5,8–10). Stress myocardial perfusion
rubidium-82 (Rb-82) positron emission tomography
(PET) has emerged as an imaging modality that is
increasingly performed across the United States, with
utilization in approximately 200 imaging centers. A recent
meta-analysis reported that the diagnostic accuracy of
PET imaging was high, with sensitivity and speciﬁcity
measurements of 92% and 85% (11). PET has several
advantages when compared with SPECT, including
excellent image quality, sizeable reductions in attenuation
artifact (12), and, importantly, an improved safety proﬁle
with an estimated effective radiation exposure dose ofw3
mSv with Rb-82 (13–17), which may proffer a signiﬁcant
advantage in the evaluation of women with suspected
myocardial ischemia (13,18).
See page 1877
There has been growing evidence regarding the prognostic
accuracy of stress myocardial perfusion Rb-82 PET, with
limited evidence as to differences in risk stratiﬁcation in key
patient subsets, including women, despite clinical use of Rb-82
for more than 2 decades (19–24). The multicenter PET
prognosis registry was undertaken to increase our evidence base
regarding the relationship between the extent and severity of
stress myocardial perfusion abnormalities and coronary artery
disease (CAD) mortality (25). An additional aim of this
registrywas to compare risk stratiﬁcationwith stressmyocardial
perfusion Rb-82 PET imaging ﬁndings in women and men.
Methods
Registry methods. The methods for this prospective, ob-
servational registry have been previously reported (25). In
brief, 4 centers participated in this registry of prospectively
enrolled patients clinically referred for stress myocardial
perfusion Rb-82 PET who were clinically followed for the
occurrence of death related to CAD (N ¼ 6,037). An
additional endpoint of death from all causes was also
ascertained. These cumulative data represent patient series
that were previously reported (19,24–26). For each center,
all consecutive patients were prospectively enrolled. All
participating centers had institutional review board approval
for the procedural and follow-up study methods. The
representation of women from each site was 44% to 55% of
their entire patient series, reﬂecting similar representation of
women across participating sites.
Collection of clinical history data. All centers applied
similar standardized methods for data collection of clinical
history, cardiac risk factors, medication use, and stress hemo-
dynamic data. Physician-interpreted typical angina or itsischemic equivalent, deﬁned as
excessive dyspnea on exertion, was
also reported. A prior diagnosis of
obstructive CAD and history of
coronary revascularization was
documented. Prescribed anti-
ischemic and preventive thera-
pies taken at the time of the
procedure were recorded. On the
basis of the patient’s age, sex, and
typicality of chest pain symptoms,
we calculated the pre-test CAD
likelihood (27).
Myocardial perfusion PET
imaging protocol. All patients
underwent Rb-82 myocardial perfusion PET using dedi-
cated or hybrid PET and computed tomography scanners, as
previously reported. Rb-82 was intravenously injected, and
standardized rest and pharmacological stress (e.g., adeno-
sine, dipyridamole) imaging protocols were uniformly per-
formed at each participating center, according to the
American Society of Nuclear Cardiology guidelines (28).
Rest and stress images were visually scored using the 17-
segment scoring system, and the percentage of abnormal
myocardium at stress was determined from the summed
stress score (10). For this analysis, we classiﬁed the per-
centage of abnormal myocardium at stress into categories of
0%, 0.1% to 4.9%, 5% to 9.9%, 10% to 14.9%, and 15%,
respectively (29,30). In a subset of 2,101 patients, rest left
ventricular ejection fraction (LVEF) was calculated. A rest
LVEF 45% was considered abnormal.
Follow-up methods. All patients were followed for a
median of 2.2 years (interquartile range: 1.3 to 3.3 years) for
CAD-related death. Each site trained study coordinators to
use standardized methods for ascertainment of mortality
status. Each site developed a telephone follow-up method
for research coordinators that included the use of a scripted
interview with the patient or family member. Each site
conﬁrmed the cause of death by review of source docu-
mentation (i.e., medical records) or conﬁrmation from the
referring physician. A fatal myocardial infarction was clas-
siﬁed as a CAD death. Patients with CAD who had heart
failure reported as the cause of death were also coded as
CAD deaths. A witnessed sudden cardiac death was also
coded as a CAD death. All other deaths were categorized as
all-cause deaths. For conﬁrmatory purposes, each U.S. site
queried the National Death Index for ascertainment of
survival status.
Statistical analysis. All analyses were conducted by using
standardized data analytic methods. Categorical variables
were compared using chi-square test likelihood ratio statis-
tics; continuous variables were compared using the non-
parametric, Wilcoxon signed rank test.
The primary endpoint for this analysis was CADmortality.
A total of 54 and 115 CAD deaths were observed during
follow-up in women and men. For the subset analysis with
Table 1
Sex Differences in Clinical Presentation for Patients Clinically Referred to
Rb-82 Myocardial Perfusion PET
Women
(n ¼ 2,904)
Men
(n ¼ 3,133) p Value
Age (yrs) 63.5  13 62.5  13 <0.0001
Hypertension 70% 66% <0.0001
Obesity (30 kg/m2) 47% 38% <0.0001
Dyslipidemia 61% 66% <0.0001
Diabetes 27% 27% 0.72
Current smoker 24% 19% <0.0001
Typical angina or dyspnea 69% 60% <0.0001
Known CAD 24% 40% <0.0001
Prior MI 16% 25% <0.0001
Prior revascularization 19% 34% <0.0001
Prior PCI 13% 21% <0.0001
Prior CABG 8% 18% <0.0001
Pre-test CAD likelihood <0.0001
Low 38% 27%
Intermediate 26% 16%
High 36% 57%
Medical therapy
Aspirin 47% 55% <0.0001
Diuretic 32% 25% <0.0001
Beta-blocker 46% 50% 0.002
Calcium-channel blocker 24% 21% 0.001
ACE inhibitor 31% 38% <0.0001
Nitroglycerin 17% 15% 0.01
Statin 51% 60% <0.0001
Heart rate (beats/min)
Rest 70  12 67  12 <0.0001
Peak stress 89  16 84  16 <0.0001
Blood pressure (mm Hg)
Rest 138  24/72  18 132  23/72  12 <0.0001/0.46
Peak stress 130  24/67  13 125  22/66  13 <0.0001/0.51
Rest left ventricular EF
(n ¼ 2,101) 63.0%  12% 51.6%  14% <0.0001
EF 45% 8.6% 27.6% <0.0001
Summed rest score <0.0001
0% 68.0% 50.9%
0.1%–4.9% 22.7% 29.8%
5.0%–9.9% 4.2% 7.4%
10.0%–14.9% 1.9% 4.1%
15.0% 3.1% 7.8%
Summed stress score <0.0001
0% 55.6% 36.1%
0.1%–4.9% 25.1% 26.7%
5.0%–9.9% 7.9% 11.3%
10.0%–14.9% 3.9% 8.2%
15.0% 7.6% 17.7%
Values are mean  SD or %. For this tabular analysis, categorical variables were compared using a chi-square test likelihood ratio statistic; with
exception age, heart rate, and blood pressure were compared using analysis of variance techniques.
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; MI ¼ myocardial infarction;
PET ¼ positron emission tomography; PCI ¼ percutaneous coronary intervention; Rb-82 ¼ rubidum-82.
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1868rest LVEF data, 16 women and 38 men experienced CAD
death during follow-up. The time to CAD death was esti-
mated using a Cox proportional hazards survival model,
including assessment of univariable and multivariable associ-
ations between clinical and PET imaging variables with CAD
mortality. From the Cox proportional hazards survivalmodels, survival curves were plotted. Multivariable model
covariates included: age, CAD risk factors, and symptoms. A
stratiﬁed Cox proportional hazards survival model was used to
plot different survival curves by sex. Separate Cox propor-
tional hazards survival models for women and men were also
derived to plot mortality differences by PET imaging data.
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1869Given that revascularization has not been associated with
improved survival when compared with medical therapy in
stable ischemic heart disease trials, we decided not to censor
for revascularization in our prognostic modeling. Model
overﬁtting was considered by limiting each model to only 1
variable for every 10 deaths. We limited our multivariable
model to only 5 variables, given the 54 deaths in women. To
that end, we did not include a history of CAD, as evidence of
ﬁxed or scarred myocardium would be summarized within the
percentage of the abnormal stress myocardium variable. In the
current analysis, the site was not included in our multivariable
model, as it was not a predictor of mortality for women
(p ¼ 0.49) or men (p ¼ 0.55). In each model, the propor-
tional hazards assumption was met. The hazard ratio and
95% conﬁdence intervals were calculated from the Cox
proportional hazards survival models. A ﬁrst-order interaction
term of sex by percentage of the stress myocardium that was
abnormal was included in the model. From the multivariable
model, predicted survival probabilities were calculated.
Annual CAD mortality was calculated as: ([1 - predicted
survival probabilities]/observed follow-up time) *100. Annual
CAD mortality was categorized as <1.0%, 1.0% to 3.0%, and
>3.0% per year, respectively (31).
A total of 193 and 283 all-cause deaths were observed in
the 6,037 women and men during follow-up. We developed
separate Cox proportional hazards multivariable models for
women and men with the covariates of age, symptoms,
smoking, and diabetes included with the percentage of
abnormal stress myocardium. We also performed a set ofFigure 1 Frequency of % Myocardium Abnormal by Sex and Pretest
Differences in the prevalence of percentage of abnormal stress myocardium for women a
disease; Rb-82 PET ¼ rubidum-82 positron emission tomography.prognostic models, including rest LVEF with the stated
covariates. For this latter subset, 68 and 95 women and men
were reported as dead during follow-up.
We calculated the net re-classiﬁcation improvement index
(NRI) using standardized approaches (32–34). For this
analysis, we compared a clinical model (i.e., model 1),
including age, cardiac risk factors, symptoms, and history of
CAD with a clinical plus stress myocardial perfusion
imaging model, including model 1 variables plus percentage
of the stress myocardium that was abnormal, and heart rate
and blood pressure measurements during testing (i.e., model
2). The corrected number of cases of newly identiﬁed lower
risk, when comparing model 2 with model 1, was deﬁned as
the number of cases with downward re-classiﬁcation for
patients without CAD mortality minus the number of
cases with upward re-classiﬁcation for patients without
CAD death. The corrected number of cases of newly
identiﬁed higher risk when comparing model 2 with model
1 was deﬁned as the number of cases with upward re-clas-
siﬁcation for patients with CAD mortality minus the
number of cases with downward re-classiﬁcation for patients
without CAD death. The NRI was calculated by adding the
newly identiﬁed lower risk plus higher risk and dividing this
by the total sample size. Categories for the NRI included
annual CAD mortality of <1.0%, 1.0% to 3.0%, and >3.0%
per year, respectively (31). We also calculated the continuous
NRI. Dr. Pencina kindly provided the SAS (SAS Institute,
Cary, North Carolina) macros for the NRI analysis using
survival data.Risk
nd men undergoing stress myocardial perfusion Rb-82 PET. CAD ¼ coronary artery
Figure 2 CAD Survival by Sex
Cumulative cardiac mortality for women and men undergoing stress Rb-82
myocardial perfusion PET imaging. Abbreviations as in Figure 1.
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1870Results
Clinical and PET descriptive statistics. The enrolled
2,904 women were generally older and more often obese,
whereas the men had a greater prevalence of known CAD,
including more often prior revascularization (Table 1). More
than half of the 3,133 men had a high pre-test CAD like-
lihood, whereas approximately one-third of women were
at low pre-test CAD likelihood. Women had a higher
prevalence of low-risk Rb-82 PET ﬁndings with moreFigure 3 Cumulative Cardiac Mortality Rates by % the Abnormal Str
Cumulative cardiac mortality rates by percentage of abnormal stress myocardium with Rb-
are reported in Figure 2. Abbreviations as in Figure 1.than half having 0% abnormal myocardium at stress, as
compared with only approximately one-third of men (Fig. 1)
(p < 0.0001). Approximately 1 in 10 women and 1 in 4 men
had a moderately to severely abnormal Rb-82 PET scan
(i.e., 10% abnormal myocardium at stress).
CAD mortality by sex and stress myocardial perfusion
Rb-82 PET. The CAD mortality was signiﬁcantly less in
women than in men. The cumulative 5-year CAD mortality
rate was 3.7% for women and 6.0% for men (p < 0.0001)
(Fig. 2). Overall CADmortality was 0.1%, 3.4%, and 5.8% for
low, intermediate, and high pre-test CAD likelihood for
women, respectively (p < 0.0001), whereas overall CAD
mortality was 1.2%, 3.9%, and 8.8% for men, respectively
(p < 0.0001). Figure 3 plots the results from a stratiﬁed Cox
proportional hazards survival model for women and men
by percentage of abnormal myocardium at stress (overall
p< 0.001). The unadjusted CADmortality rates ranged from
0.9% to 12.9% for women (p < 0.0001) and from 1.5% to
17.4% for men (p < 0.0001) for 0% to 15% abnormal
myocardium at stress. The relative hazard for 10% to 19.9%
and20% abnormal stress myocardium was 11.5 and 14.3 for
women (p < 0.0001) and 4.8 and 9.3 for men (p < 0.0001).
Table 2 reports the univariable and multivariable Cox
proportional hazards survival model results including
percentage of abnormal myocardium at stress. In unadjusted
and adjusted models, the percentage of abnormal stress
myocardium was a signiﬁcant estimator of time to CAD
mortality for both women and men. A ﬁrst-order interaction
term of sex by percentage of the stress myocardium that was
abnormal was nonsigniﬁcant (p ¼ 0.39). In Figure 4, for
women, the annual CAD mortality rose from 0.23% to
3.73% as the percentage of abnormal myocardium at stressess Myocardium With Rb-82 PET Imaging
82 PET imaging. Stratiﬁed Cox model chi-square ¼ 154, p < 0.0001. Number at risk
Table 2 Unadjusted and Adjusted Hazard for CAD Death in Women and Men Undergoing Stress Myocardial Perfusion Rb-82 PET Imaging
Women Men
Hazard ratio 95% CI p Value Hazard ratio 95% CI p Value
I. Unadjusted model d separate models for
women and men
Percentage of abnormal stress (per 5% of the myocardium)* 1.81 1.54–2.14 <0.0001 1.71 1.52–1.94 <0.0001
Univariable model Chi-square test ¼ 61 (p < 0.0001) Chi-square test ¼ 89 (p < 0.0001)
II. Clinically adjusted modely d separate models for
women and men
Percentage of abnormal stress (per 5% of the myocardium) 1.59 1.34–1.88 <0.0001 1.55 1.37–1.76 <0.0001
Multivariable modely Chi-square test ¼ 106 (p < 0.0001) Chi-square test ¼ 147, (p < 0.0001)
III. Multivariable model with interaction term (N ¼ 6,037)z
First order sex interaction term Sex by percentage of abnormal stress myocardium
(p ¼ 0.39)
*Truncated at 15% of the myocardium. yCovariates in the model included age, typical angina/dyspnea, smoking, and diabetes. zThis model included percentage of abnormal stress myocardium, sex, and
an interaction term of sex by % abnormal stress myocardium.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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1871increased from 0% to 50%. For men, the annual CAD
mortality increased from 0.56% to 4.09% as the percentage
of abnormal myocardium at stress increased from 0% to 50%.
We also performed a subset analysis of patients with rest
LVEF measurements (n ¼ 2,101). Table 3 reports the Cox
proportional hazards survival models estimating CAD
mortality in women and men. For both women and men,
the combined measurement of rest LVEF and stress
myocardial perfusion abnormalities (i.e., percentage of
myocardium abnormal) were strong estimators of CAD
mortality. When LVEF was added to the model, the
inclusion of percentage of stress myocardium that was
abnormal remained independently signiﬁcant for the esti-
mation of CAD mortality for both women (p ¼ 0.001) and
men (p ¼ 0.01). There was the commonly observed inverse
relationship between depressed LVEF and increased CADFigure 4 Predicted CAD Mortality by % Abnormal Myocardium at Str
Scatterplot of the predicted cardiac mortality per year (and 95% conﬁdence intervals) by th
and 3,133 men. An exponential trendline was used to plot CAD mortality for women andmortality. From the predicted model, the inverse relation-
ship is plotted in Figure 5. For women with normal rest
LVEF measurements (60%), the annual CAD mortality
was <0.47%. By comparison, for women with impaired rest
LVEF, the annual CAD mortality ranged from 2.4% to as
high as 15.2% for LVEF measurements from 45% to 20%
(p < 0.0001). A similar relationship was noted for men.
The data are not shown, but the percentage of abnormal
stress myocardium was also predictive in adjusted models
estimating all-cause mortality (p < 0.0001 for separate
models for women and men). In this adjusted all-cause
mortality model in women, there was a 2.9% increase in
all-cause death risk for every 1% increase in the percentage of
abnormal stress myocardium (hazard ratio: 1.03, 1.02 to
1.04; p < 0.0001). Similarly for men, there was a 2.2%
increase in all-cause death risk for every 1% increase in theess
e percentage of abnormal myocardium by stress Rb-82 PET imaging in 2,904 women
men. Abbreviations as in Figure 1.
Table 3 Model Subset Including Rest LVEF Measurement and Stress Myocardial Perfusion Rb-82 PET in 2,101 Women and Men
Women Men
Hazard ratio 95% CI p Value Hazard ratio 95% CI p Value
I. Multivariable model d separate models for women and men
Rest LVEF 45% 0.75 0.62–0.90 0.002 0.74 0.65–0.85 <0.0001
Percentage of abnormal stress (per 5% of the myocardium)* 1.81 1.54–2.14 0.001 1.43 1.08–1.89 0.011
Model results Chi-square test ¼ 68 (p < 0.0001) Chi-square test ¼ 55 (p < 0.0001)
II. Multivariable model with interaction term (N ¼ 6,037)**
First order sex interaction term Sex by rest LVEF
(p ¼ 0.44)
*Truncated at 15% of the myocardium. **This model included rest LVEF, sex, and an interaction term of sex by rest left ventricular ejection fraction (LVEF).
Abbreviations as in Table 1.
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1872percentage of abnormal stress myocardium (hazard ratio:
1.022, 1.01 to 1.03; p < 0.0001). For rest LVEF, the
relative hazard for all-cause mortality was 0.98 (95% CI:
0.97 to 0.99; p ¼ 0.002) for men and 0.96 (95% CI: 0.95 to
0.98; p < 0.0001) for women.
NRI. When compared with a clinical risk model (including
age, risk factors, and symptoms), the addition of stress
myocardial perfusion Rb-82 PET data provided improve-
ment in risk re-classiﬁcation for both women and men
(Table 4). For women, the inclusion of PET data within
a clinical risk model improved the detection of high-risk
patients (9.3% newly detected), which was more than for
men (3.5% newly detected). Conversely, the inclusion of
PET data within a clinical risk model improved the detec-
tion of low-risk men (11.5% newly detected), which was
more than the detection of low-risk women (3.4% newly
detected). The overall categorical NRI for women was 0.115
(95% conﬁdence interval [CI]: 0.0135 to 0.249); the NRI
for men was higher at 0.168 (95% CI: 0.063 to 0.27). There
is minimal overlap in the conﬁdence intervals for the NRIFigure 5 Predicted CAD Mortality by Rest Left Ventricular Ejection F
Scatterplot of the predicted cardiac mortality per year (and 95% conﬁdence intervals) by
LV ¼ left ventricular; other abbreviations as in Figure 1.measure for women and men. The difference between the
clinical history model and a model adding PET variables was
statistically signiﬁcant for women (p ¼ 0.001) and men
(p < 0.0001). The continuous NRI for women was 0.392
(95% CI: 0.115 to 0.706); the NRI for men was higher at
0.640 (95% CI: 0.425 to 0.837).
Age subset analyses. The predicted annual CAD mortality
by age deciles is reported in Figure 6 (noting that the CAD
mortality rates are based on a predicted model including age,
sex, and percentage of abnormal myocardium at stress for
Rb-82 PET). For both women and men, there was a direct
proportional relationship between increasingly abnormal
stress myocardium and increasing age. For the oldest group
of women (age 80 years) with a moderately to severely
abnormal stress Rb-82 PET (i.e., 10% of the myocar-
dium), the annual adjusted CAD mortality was 7.4%.
This may be compared to an annual, adjusted CAD
mortality of 10.7% in the corresponding group of men with
a moderately to severely abnormal stress Rb-82 PET.
Conversely, the event rates were very low in women <50raction
rest LV ejection fraction Rb-82 PET imaging in 2,101 women and men.
Table 4
Net Re-Classiﬁcation Improvement for Estimation of
CAD Death Using Clinical Risk Variables Combined
With Stress Myocardial Perfusion Rb-82 PET Imaging
in Women and Men
Women d Detection of Low Risk*
Clinical þ Nuclear Risk
<1.0% 1.0%–3.0% >3.0% Totals
Clinical risk <1.0% 1,572 55 0 1,627
1.0%–3.0% 100 610 35 745
>3.0% 0 86 392 478
Totals 1,672 751 427 2,850
Detection of Low Risk
Concordant 2,574 (90.3%)
Discordant 276 (9.7%)
Percentage of patients newly detected as low risk 3.4%
Detection of High Risky
Clinical þ Nuclear Risk
<1.0% 1.0%–3.0% >3.0% Totals
Clinical risk <1.0% 15 3 0 18
1.0%–3.0% 0 14 4 18
>3.0% 0 2 16 18
Totals 15 19 20 54
Detection of High Risk
Concordant 45 (83.3%)
Discordant 9 (16.7%)
Percentage of patients newly detected as high risk 8.1%
Categorical NRI ¼ 0.115 (95% CI: 0.014 to 0.249)
Men d Detection of Low Risk*
Clinical þ Nuclear Risk
<1.0% 1.0%–3.0% >3.0% Totals
Clinical risk <1.0% 870 36 5 911
1.0%–3.0% 233 724 76 1,033
>3.0% 0 231 843 1,074
Totals 1,103 991 924 3,018
Detection of Low Risk
Concordant 2,437 (80.7%)
Discordant 581 (19.3%)
Percentage of patients newly detected as low risk 11.6%
Detection of High Risky
Clinical þ Nuclear Risk
<1.0% 1.0%–3.0% >3.0% Totals
Clinical risk <1.0% 19 6 2 27
1.0%–3.0% 2 16 8 26
>3.0% 0 10 52 62
Totals 21 32 62 115
Detection of High Risk
Concordant 87 (75.6%)
Discordant 28 (24.3%)
Percentage of patients newly detected as high risk 5.3%
Categorical NRI ¼ 0.168 (95% CI: 0.063 to 0.275). *For low risk, detection of a correct control is
deﬁned as movement to a lower-risk category for a surviving patient; detection of an incorrect
control is deﬁned as movement to a higher-risk category for a surviving patient. yFor high risk,
detection of a correct case is deﬁned as movement to a higher-risk category for a patient that died
of cardiac causes during follow-up; detection of an incorrect case is deﬁned as movement to
a lower-risk category for a patient that died of cardiac causes during follow-up.
NRI ¼ net re-classiﬁcation improvement; other abbreviations as in Table 1.
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3 years of follow-up in 829 women <55 years of age.
Accordingly, the percentage of abnormal myocardium at
stress was of borderline signiﬁcance (p ¼ 0.063) for younger
women, but it was highly signiﬁcant for women 55 years
(p < 0.0001). For women 55 years of age, the NRI was
0.21 (0.09 to 0.34), including 17% of CAD deaths and
3.9% of CAD survivors correctly re-classiﬁed. There is
considerable overlap in the conﬁdence intervals for this NRI
analysis in women 55 years of age and for that reported in
men (see as previously described).
Discussion
Over the last few decades, there has been a growing body of
evidence regarding effective risk stratiﬁcation of women
on the basis of CAD stress imaging ﬁndings (1,8,9,35–38).
This evidence is important due to the historic underrepre-
sentation of women in clinical research and the reported
limited diagnostic accuracy of stress testing in female cohorts
(1,39). Stress myocardial perfusion SPECT has been the
mainstay of nuclear imaging practice for several decades, with
extensive evidence on accurate prognostication in women and
men (1,23,26,40). Stress myocardial perfusion PET has
a limited evidence base, but it may have advantages in the
evaluation of women due to the reported improved image
quality (e.g., better spatial resolution and a reduced prevalence
of artifacts) (12), high diagnostic accuracy (11), and an
improved safety proﬁle (with a low effective radiation dose of
Rb-82 at w3 mSv) (18,21). Our results reveal that the
percentage of abnormal stress myocardium with Rb-82 PET
was independently predictive of CAD mortality for women
and men, and it is important that a test for interaction by sex
was nonsigniﬁcant. The observed ﬁndings noted a propor-
tional relationship between CAD mortality and stress Rb-82
PET myocardial defect size and extent, as measured by
percentage ofmyocardial involvement. The unadjusted 5-year
CAD mortality ranged from 0.9% to 12.9% for women
(p< 0.0001) and from to 1.5% to 17.4% formen (p< 0.0001)
for 0% to15% abnormal myocardium at stress (Fig. 3). The
data present similar ﬁndings to stress myocardial perfusion
SPECT, with annual CAD mortality rates increasing in
a similar proportional manner with the percentage of
abnormal myocardium at stress (10,40,41).
Sex equity in prognostic accuracy. Recently, there have
been several reports noting effective risk stratiﬁcation for
women and men clinically referred for stress imaging
(1,8,35,36). This equivalent ability to stratify womenwith stress
imaging modalities is important in large part because of the
challenges in accuracy of qualitative descriptors of the present-
ing symptoms of women, decreased functional capabilities, and
underlying comorbidities that contribute to limitations in
provocative stress testing for women (14). The current prog-
nostic registry data with stress myocardial perfusion Rb-82
PET now add to the literature of stress echocardiography,
magnetic resonance imaging, and SPECT (1,18,38,39).
Figure 6
Gradient CAD Mortality Relationship Between Abnormal Stress Myocardial Perfusion Results (by Percentage of
Myocardium) and Age (in Deciles)
This ﬁgure shows a directly proportional relationship between older age and higher CAD mortality with more extensive and severely abnormal stress myocardial perfusion Rb-82
PET imaging results. These rates are predicted and annualized from a Cox model containing age, sex, and percentage of abnormal myocardium. Abbreviations as in Figure 1.
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the value of stress myocardial perfusion SPECT for risk
stratiﬁcation in women and men (41–47). Our study
suggests that myocardial perfusion PET provides compa-
rably effective risk stratiﬁcation while also improving the
overall safety proﬁle of the index stress imaging examination,
with an effective radiation dose ofw3 mSv for Rb-82 PET
as compared with w12 mSv for Tc-99m SPECT
(13,15,16,18,48–50). For normal stress myocardial perfusion
SPECT results, the annual CAD event rates have been
consistently low and <1%, which are similar to the results of
our observed ﬁndings with PET imaging (36,46,51). Across
the age groups, a normal stress myocardial perfusion PET
study was associated with a low CAD mortality. Moreover,
as the extent and severity of perfusion abnormalities worsen,
there is a gradient increase in CAD events for both SPECT
and PET. From 1 report, the annual CAD mortality
was elevated approximately 6- to 9-fold for women with
moderately or severely abnormal as compared with normal
adenosine myocardial perfusion SPECT (41). Similarly, in
the current series, the relative hazard for 10% to 19.9%
and 20% abnormal stress myocardium was 11.5 and 14.3
for women (p < 0.0001).
Risk re-classiﬁcation, age, and CAD death risk. We
extended previous ﬁndings to examine changes in CAD
mortality by age. In the current series, CAD death rates
were low for younger patients, but the rates increased for
older women and men. For the oldest group of women(age 80 years) with a moderately or severely abnormal
stress Rb-82 PET (i.e., 10% of the myocardium), the
adjusted CAD mortality was 11.6% per year. A similarly
high adjusted CAD mortality rate was observed for men
(15.3% per year) (Fig. 6). By comparison, only 2 CAD
deaths were observed in 829 women <55 years of age. The
result is that the overall NRI for Rb-82 PET data added to
a clinical risk model was 0.12 for women and 0.17 for men,
but the value nearly doubled to 0.21 (95% CI: 0.09 to 0.34)
for women 55 years. The data suggest that women <55
years of age, as prior evidence suggests, may beneﬁt from an
alternative diagnostic evaluation that may include non-
imaging exercise testing (40). In a recent randomized trial,
no improvement in 2-year CAD outcomes was observed for
lower-risk women undergoing exercise electrocardiography
as compared with exercise myocardial perfusion SPECT
(40). Certainly, this requires additional clariﬁcation with an
increased understanding of the role of additional CAD
endpoints beyond death; however, these data are consistent
with the body of evidence that the CAD death risk of
a woman proportionally increases with age.
Study limitations. Observational registry data are not
without issues related to the selective nature of the referral
process, the variability in post-PET management that may
inﬂuence outcome, and the lack of availability of more
detailed historical data. Although we noted several advan-
tages with PET imaging, 1 disadvantage is the inability to
perform exercise stress prior to stress imaging. Moreover,
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that may further confound the presented analysis; however,
in this registry, the site was not a signiﬁcant estimator
of mortality (31). The classiﬁcation of CAD death has stated
limitations, with the reliance on this endpoint as primary
outcome that may lead to a misclassiﬁcation of the cause of
death and an undervaluing of any prognostic relationships
(52). Interaction effects can be difﬁcult to detect, and the
current analysis may have limited statistical power to detect
an interaction by sex in our prognostic modeling. Despite
these limitations, there is (generally) improved prognostic
model statistics that suggest the use of CAD mortality as an
endpoint has reﬁned detection of risk over the less speciﬁc
all-cause mortality. Each site did not uniformly collect data
on left ventricular enlargement and transient ischemic dila-
tion. The data were not available and may have had an
impact on our prognostic models. Sites also combined the
presenting symptoms of angina and dyspnea. Separate
coding of this variable may have inﬂuenced the prognostic
models. Finally, a priori, we applied categories of predicted
CAD death to emulate population and patient risk subsets
that range from low to high risk. A decision to apply varying
categories may result in different NRI ﬁndings.
Conclusions
The current analysis compared the ability of stress myocar-
dial perfusion Rb-82 PET to detect CAD mortality risk in
women as compared with men. A test for interaction failed
to reveal any statistical difference in risk stratiﬁcation by
sex and the percentage of stress myocardium that was
abnormal. This ﬁnding of sex equity in risk stratiﬁcation
with Rb-82 supports comparability with evidence from Tc-
99m SPECT and other stress imaging modalities. Rb-82
PET ﬁndings were particularly helpful at improved detec-
tion of higher risk women 55 years of age.
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